The global market for Endovascular Aneurysm Repair was estimated at US$2.5 Billion in 2024 and is projected to reach US$3.0 Billion by 2030, growing at a CAGR of 3.3% from 2024 to 2030. This comprehensive report provides an in-depth analysis of market trends, drivers, and forecasts, helping you make informed business decisions. The report includes the most recent global tariff developments and how they impact the Endovascular Aneurysm Repair market.
Global Endovascular Aneurysm Repair Market - Key Trends & Drivers Summarized
Why Is Endovascular Aneurysm Repair Redefining Aneurysm Treatment in Vascular Medicine?
Endovascular Aneurysm Repair (EVAR) has revolutionized the management of abdominal and thoracic aortic aneurysms by providing a minimally invasive alternative to traditional open surgical repair. This technique involves inserting a stent graft through a small incision in the groin and navigating it via the femoral artery to the site of the aneurysm, where it is deployed to reinforce the weakened vessel wall and prevent rupture. EVAR offers numerous benefits over open surgery, including reduced blood loss, lower perioperative morbidity, shorter hospital stays, and faster recovery times. It is especially advantageous for elderly patients or those with comorbidities who may not tolerate major surgery. The rising global incidence of aortic aneurysms driven by aging populations, hypertension, smoking, and atherosclerosis has significantly increased the clinical need for safer, more efficient interventions like EVAR. As vascular imaging and stent-graft design continue to improve, EVAR has become the first-line treatment for many patients with suitable anatomy. Additionally, widespread screening programs and improved diagnostic imaging have led to earlier detection of asymptomatic aneurysms, expanding the potential candidate pool for EVAR procedures. As a result, EVAR is not only transforming how aneurysms are treated but also reshaping patient expectations by offering a lower-risk, high-reward path to recovery and longevity.How Are Technological Innovations Enhancing the Precision and Outcomes of EVAR Procedures?
The field of endovascular aneurysm repair is advancing rapidly, fueled by continual innovations in stent graft design, imaging technologies, and procedural techniques. Modern stent grafts are now designed with greater flexibility, durability, and conformability to accommodate a wider range of patient anatomies, including those with tortuous or angulated vessels. The advent of fenestrated and branched stent grafts has made it possible to treat aneurysms that involve or are close to major arterial branches such as the renal and iliac arteries cases that were previously deemed unsuitable for EVAR. Real-time 3D image-guided navigation systems, such as fusion imaging and intravascular ultrasound (IVUS), have dramatically improved the accuracy of graft placement, reducing complications and the need for contrast agents. Robotic-assisted and catheter-based delivery systems are enhancing precision and operator control, particularly in complex aortic anatomies. Innovations in bioresorbable materials and drug-eluting stents are also being explored to improve graft integration and reduce long-term risks such as endoleaks or graft migration. Post-procedural monitoring has benefited from advancements in wearable technology and mobile health platforms, which allow for remote follow-up and early detection of complications. Collectively, these innovations are not only improving the safety and efficacy of EVAR procedures but also expanding their applicability, pushing the boundaries of what can be achieved through endovascular intervention.Why Is the Demand for EVAR Expanding Across Demographics and Global Regions?
The demand for endovascular aneurysm repair is expanding rapidly across age groups, patient profiles, and geographic regions due to a combination of clinical, economic, and demographic factors. In high-income countries, the aging population is a key driver, with men over 65 being particularly at risk for abdominal aortic aneurysms (AAA). These nations also benefit from established screening programs, advanced imaging capabilities, and access to specialized vascular centers, enabling early diagnosis and elective EVAR before rupture occurs. In contrast, emerging economies are seeing a surge in cardiovascular risk factors including diabetes, hypertension, and smoking contributing to a growing aneurysm burden. As healthcare infrastructure improves and access to endovascular procedures increases, these markets represent significant growth opportunities for EVAR technologies. Moreover, the adoption of EVAR is extending beyond tertiary care centers to regional and community hospitals, supported by advancements in training, procedural standardization, and simplified stent-graft systems. Patients are also playing a more active role in treatment decisions, with many favoring minimally invasive options that allow for quicker recovery and less postoperative pain. In younger patients with connective tissue disorders or traumatic aortic injuries, off-label use of EVAR is being explored with promising outcomes. From military medicine to disaster response and mobile surgical units, the versatility of EVAR makes it highly adaptable across diverse healthcare environments, further driving global demand.What Factors Are Fueling the Accelerated Growth of the Endovascular Aneurysm Repair Market?
The growth in the endovascular aneurysm repair market is driven by a convergence of technological, clinical, economic, and regulatory factors that collectively point to an expanding and maturing field. One of the most significant growth drivers is the increasing prevalence of aortic aneurysms, particularly in aging populations and among individuals with cardiovascular risk factors. Healthcare providers are increasingly opting for EVAR over open surgery due to its lower complication rates, shorter recovery time, and reduced hospital resource utilization factors that align well with value-based healthcare models and cost-containment initiatives. Regulatory approvals and reimbursement policies are also playing a crucial role, with more EVAR devices receiving clearance for broader anatomical indications and being included in insurance coverage plans. The rise of outpatient vascular surgery centers and hybrid operating rooms has made it more feasible for hospitals to adopt EVAR without major infrastructure overhauls. Additionally, increased awareness among both physicians and patients regarding aneurysm symptoms, risk factors, and screening recommendations is driving earlier diagnosis and timely intervention. Medical device companies are investing heavily in R&D to develop next-generation grafts and delivery systems, creating a pipeline of innovations that promise to reduce procedural complexity and long-term complications. As clinical guidelines continue to favor minimally invasive solutions and global healthcare systems pivot toward proactive, preventative care, EVAR is poised for sustained, high-growth momentum across both mature and emerging markets.Key Insights:
- Market Growth: Understand the significant growth trajectory of the Abdominal Aortic Aneurysm segment, which is expected to reach US$1.6 Billion by 2030 with a CAGR of a 3.0%. The Thoracic Aortic Aneurysm segment is also set to grow at 3.9% CAGR over the analysis period.
- Regional Analysis: Gain insights into the U.S. market, valued at $677.6 Million in 2024, and China, forecasted to grow at an impressive 6.1% CAGR to reach $596.8 Million by 2030. Discover growth trends in other key regions, including Japan, Canada, Germany, and the Asia-Pacific.
Why You Should Buy This Report:
- Detailed Market Analysis: Access a thorough analysis of the Global Endovascular Aneurysm Repair Market, covering all major geographic regions and market segments.
- Competitive Insights: Get an overview of the competitive landscape, including the market presence of major players across different geographies.
- Future Trends and Drivers: Understand the key trends and drivers shaping the future of the Global Endovascular Aneurysm Repair Market.
- Actionable Insights: Benefit from actionable insights that can help you identify new revenue opportunities and make strategic business decisions.
Key Questions Answered:
- How is the Global Endovascular Aneurysm Repair Market expected to evolve by 2030?
- What are the main drivers and restraints affecting the market?
- Which market segments will grow the most over the forecast period?
- How will market shares for different regions and segments change by 2030?
- Who are the leading players in the market, and what are their prospects?
Report Features:
- Comprehensive Market Data: Independent analysis of annual sales and market forecasts in US$ Million from 2024 to 2030.
- In-Depth Regional Analysis: Detailed insights into key markets, including the U.S., China, Japan, Canada, Europe, Asia-Pacific, Latin America, Middle East, and Africa.
- Company Profiles: Coverage of players such as Abbott Laboratories, Bolton Medical, Inc., Boston Scientific Corporation, C.R. Bard (a BD company), and more.
- Complimentary Updates: Receive free report updates for one year to keep you informed of the latest market developments.
Some of the 36 companies featured in this Endovascular Aneurysm Repair market report include:
- Abbott Laboratories
- Bolton Medical, Inc.
- Boston Scientific Corporation
- C.R. Bard (a BD company)
- Cardinal Health, Inc.
- Cook Medical LLC
- Cordis Corporation (Johnson & Johnson)
- Endologix, Inc.
- Endospan Ltd.
- Getinge AB
- JOTEC GmbH
- L. Gore & Associates, Inc. (Gore Medical)
- Lombard Medical Limited
- Medtronic plc
- Philips Healthcare
- Shanghai MicroPort Medical (Group) Co., Ltd.
- Teleflex Incorporated
- Terumo Corporation
- TriVascular Technologies, Inc.
- Volcano Corporation (a Philips company)
This edition integrates the latest global trade and economic shifts as of June 2025 into comprehensive market analysis. Key updates include:
- Tariff and Trade Impact: Insights into global tariff negotiations across 180+ countries, with analysis of supply chain turbulence, sourcing disruptions, and geographic realignment. Special focus on 2025 as a pivotal year for trade tensions, including updated perspectives on the Trump-era tariffs.
- Adjusted Forecasts and Analytics: Revised global and regional market forecasts through 2030, incorporating tariff effects, economic uncertainty, and structural changes in globalization. Includes segmentation by product, technology, type, material, distribution channel, application, and end-use, with historical analysis since 2015.
- Strategic Market Dynamics: Evaluation of revised market prospects, regional outlooks, and key economic indicators such as population and urbanization trends.
- Innovation & Technology Trends: Latest developments in product and process innovation, emerging technologies, and key industry drivers shaping the competitive landscape.
- Competitive Intelligence: Updated global market share estimates for 2025, competitive positioning of major players (Strong/Active/Niche/Trivial), and refined focus on leading global brands and core players.
- Expert Insight & Commentary: Strategic analysis from economists, trade experts, and domain specialists to contextualize market shifts and identify emerging opportunities.
- Complimentary Update: Buyers receive a free July 2025 update with finalized tariff impacts, new trade agreement effects, revised projections, and expanded country-level coverage.
Table of Contents
I. METHODOLOGYII. EXECUTIVE SUMMARY2. FOCUS ON SELECT PLAYERSIII. MARKET ANALYSISCANADAITALYSPAINRUSSIAREST OF EUROPESOUTH KOREAREST OF ASIA-PACIFICARGENTINABRAZILMEXICOREST OF LATIN AMERICAIRANISRAELSAUDI ARABIAUNITED ARAB EMIRATESREST OF MIDDLE EAST
1. MARKET OVERVIEW
3. MARKET TRENDS & DRIVERS
4. GLOBAL MARKET PERSPECTIVE
UNITED STATES
JAPAN
CHINA
EUROPE
FRANCE
GERMANY
UNITED KINGDOM
ASIA-PACIFIC
AUSTRALIA
INDIA
LATIN AMERICA
MIDDLE EAST
AFRICA
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Abbott Laboratories
- Bolton Medical, Inc.
- Boston Scientific Corporation
- C.R. Bard (a BD company)
- Cardinal Health, Inc.
- Cook Medical LLC
- Cordis Corporation (Johnson & Johnson)
- Endologix, Inc.
- Endospan Ltd.
- Getinge AB
- JOTEC GmbH
- L. Gore & Associates, Inc. (Gore Medical)
- Lombard Medical Limited
- Medtronic plc
- Philips Healthcare
- Shanghai MicroPort Medical (Group) Co., Ltd.
- Teleflex Incorporated
- Terumo Corporation
- TriVascular Technologies, Inc.
- Volcano Corporation (a Philips company)
Table Information
Report Attribute | Details |
---|---|
No. of Pages | 276 |
Published | June 2025 |
Forecast Period | 2024 - 2030 |
Estimated Market Value ( USD | $ 2.5 Billion |
Forecasted Market Value ( USD | $ 3 Billion |
Compound Annual Growth Rate | 3.3% |
Regions Covered | Global |